Mission Bio

Executive Summary

Mission Bio is a pioneering single-cell multi-omics company that commercializes the Tapestri Platform, enabling simultaneous detection of SNVs, CNVs, and proteins from individual cells. This platform uniquely connects genotype to phenotype, addressing critical needs in cancer research (e.g., hematologic malignancies, solid tumors) and genome editing quality control. Founded in 2014 and headquartered in South San Francisco, the company has established itself as a key player in the rapidly growing single-cell analysis market, which is driven by demand for deeper biological insights and precision medicine. The Tapestri Platform's ability to deliver multi-modal data from the same cell offers a competitive advantage over single-omics approaches, positioning Mission Bio for continued adoption across academic and pharmaceutical research. While the company remains private and has not disclosed recent financials, its technology is well-positioned to capitalize on expansions into liquid biopsy and clinical applications, pending further development and partnerships.

Upcoming Catalysts (preview)

• Q3 2026Strategic partnership with a top pharmaceutical company for liquid biopsy development40% success
• Q4 2026Launch of a next-generation Tapestri platform with improved throughput and multi-omics capabilities50% success
• TBDFDA approval for a diagnostic application using Tapestri in minimal residual disease monitoring20% success